-
Ladenburg Thalmann On Biotech: Buy BioCryst, Albireo Shares
Thursday, February 16, 2017 - 12:27pm | 474Read More...Biotechnology stocks have experienced high price and volume fluctuations that “have often been unrelated or disproportionate to the operating performance of companies, ” according to Ladenburg Thalmann analysts. Against this backdrop, Ladenburg Thalmann initiated coverage of two biotech...
-
XOMA Challenged With A 'Major Financing Overhang'
Tuesday, November 15, 2016 - 11:39am | 330Read More...XOMA Corp (NASDAQ: XOMA) appears to have a “significant financing overhang,” having reported net loss of $12.5 million during Q3:16 and ending the quarter with $20.6 million in cash. Ladenburg Thalmann’s Matthew L. Kaplan maintains a Neutral rating on the company. Q3 And Overhang...
-
Keryx's Auryxia Supply Issues Overshadow 'Strong' Q2 Earnings
Tuesday, August 2, 2016 - 8:18am | 301Read More...Although Keryx Biopharmaceuticals (NASDAQ: KERX) reported higher-than-expected sales for 2Q, Auryxia supply issues may significantly impact the company’s US revenues from mid-August onward, Ladenburg Thalmann’s Matthew L. Kaplan said in a report. He maintained a Buy rating on the...
